TUESDAY DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RVNC

Author's Avatar
Feb 06, 2022

%3Cb%3ERobbins+Geller+Rudman+%26amp%3B+Dowd+LLP%3C%2Fb%3E announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (“Class Period”) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc., No. 21-cv-09585 (N.D. Cal.). Commenced on December 10, 2021, the Revance Therapeutics class action lawsuit charges Revance Therapeutics along with certain of its top executives with violations of the Securities Exchange Act of 1934.